SyntheticMR reported its full Q4, showing headline figures in line with preliminary figures. Further details show positive sales development in Europe and APAC, while Americas remain sluggish. The company has completed the rights issue, injecting SEK 33m before fees, and says it has a clear plan to reach profitability without further injections.

Länk till analysen